A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

NCT06067828 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate
DRUG: Treatment B: Budesonide and Formoterol Fumarate
DRUG: Treatment C : Placebo

Sponsor

AstraZeneca